Growth hormone and cardiovascular health are connected through several endocrine pathways that influence cardiac muscle, blood vessels and metabolic regulation. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) contribute to normal cardiovascular physiology, but their effects depend on hormone concentrations, tissue responsiveness and the duration of exposure.
An important finding from human endocrine research is that both growth hormone deficiency and chronic GH excess can be associated with cardiovascular abnormalities.
The relationship is therefore not simply that higher GH produces a healthier heart.
How Does Growth Hormone Affect the Cardiovascular System?
The heart and blood vessels contain receptors involved in GH and IGF-1 signalling.
These pathways influence cardiomyocyte growth, vascular function and aspects of cardiac performance.
GH can act directly through its receptor or indirectly through circulating and locally produced IGF-1.
However, researchers have not fully established the relative contribution of each pathway to every cardiovascular response.
8 Research Findings About Growth Hormone and Cardiovascular Health
1. GH and IGF-1 Influence Cardiac Muscle Cells
Cardiomyocytes are specialised muscle cells responsible for heart contraction.
Experimental research demonstrates that GH–IGF-1 signalling influences cardiac growth and cellular activity.
IGF-1 activates intracellular pathways involved in protein synthesis and cell survival, including PI3K–Akt signalling.
These mechanisms contribute to normal cardiac development and maintenance.
However, changes in cardiomyocyte growth must be interpreted carefully because excessive growth can contribute to pathological cardiac hypertrophy.
2. Growth Hormone Deficiency Can Affect Cardiac Structure
Adults with established GH deficiency may demonstrate alterations in cardiac mass and performance.
Some studies have reported reduced left ventricular mass and impaired exercise-related cardiac responses.
These findings are not universal, and cardiovascular outcomes can be influenced by age, the duration of deficiency and other pituitary hormone abnormalities.
Importantly, observations in patients with diagnosed GH deficiency should not be generalised to healthy adults with normal endocrine function.
3. IGF-1 Participates in Vascular Signalling
IGF-1 interacts with vascular endothelial cells and smooth muscle cells.
Experimental studies indicate that IGF-1 can influence endothelial nitric oxide production.
Nitric oxide contributes to vascular relaxation and the regulation of blood vessel tone.
However, vascular responses depend on the wider metabolic environment, including insulin sensitivity and inflammatory activity.
Our growth hormone and IGF-1 research guide explains why these hormones should be evaluated separately.
4. Chronic GH Excess Can Cause Cardiac Hypertrophy
Acromegaly is a condition characterised by prolonged excessive GH activity, usually accompanied by elevated IGF-1.
Chronic exposure can contribute to increased cardiac muscle mass, particularly left ventricular hypertrophy.
As the condition progresses, some patients develop impaired ventricular relaxation, fibrosis or reduced cardiac performance.
The severity of these changes varies with disease duration, hormonal activity and associated cardiovascular conditions.
5. GH Excess Is Associated With Hypertension
Hypertension is an important cardiovascular complication of acromegaly.
Several mechanisms may contribute, including increased sodium retention, extracellular fluid expansion and altered vascular resistance.
GH-related insulin resistance can also influence cardiovascular regulation.
These findings demonstrate that endocrine effects on blood pressure involve interactions between renal, metabolic and vascular pathways.
For related metabolic mechanisms, see our growth hormone and insulin resistance article.
6. GH Deficiency Can Be Associated With Unfavourable Lipid Profiles
Some adults with GH deficiency demonstrate increased abdominal adiposity and elevated low-density lipoprotein cholesterol.
These changes may contribute to an unfavourable cardiovascular risk profile.
Clinical studies of GH replacement in appropriately diagnosed patients have reported improvements in selected body composition and lipid measurements.
However, improvements in intermediate risk markers do not independently establish a reduction in heart attacks, strokes or cardiovascular mortality.
Long-term cardiovascular outcomes require separate evaluation.
7. Acromegaly Can Affect Heart Rhythm and Valves
Cardiovascular research has identified associations between acromegaly and several structural or electrical cardiac abnormalities.
These include ventricular hypertrophy, valvular changes and certain arrhythmias.
Potential mechanisms involve myocardial remodelling, fibrosis and changes in cardiac conduction.
Nevertheless, the precise relationship between GH excess and individual arrhythmia outcomes remains incompletely understood.
The risk is influenced by additional factors such as hypertension, age and existing cardiovascular disease.
8. Normalising GH Activity Does Not Guarantee Complete Cardiovascular Recovery
Studies involving patients with acromegaly show that effective control of GH and IGF-1 can improve some cardiovascular abnormalities.
Changes in cardiac mass, blood pressure and metabolic risk factors have been reported following successful treatment.
However, structural abnormalities may persist, particularly after prolonged disease exposure.
Similarly, GH replacement in patients with confirmed deficiency can influence selected cardiovascular measurements without establishing universal clinical benefit.
These observations support a central conclusion: cardiovascular health depends on balanced endocrine function rather than simply maximising GH concentrations.
Growth Hormone Deficiency vs GH Excess: Cardiovascular Differences
The cardiovascular effects of abnormal GH activity differ according to the underlying endocrine condition.
| Research characteristic | GH deficiency | Chronic GH excess |
|---|---|---|
| Typical clinical context | Pituitary GH deficiency | Acromegaly |
| Cardiac structure | Reduced cardiac mass in some patients | Cardiac hypertrophy and remodelling |
| Lipid metabolism | Unfavourable lipid profiles may occur | Metabolic abnormalities may occur |
| Insulin sensitivity | Can be impaired | Frequently impaired |
| Blood pressure | Variable | Hypertension is common |
| Cardiac function | Reduced performance in some populations | Diastolic dysfunction and other abnormalities |
| Interpretation | Depends on deficiency severity and comorbidities | Depends on exposure duration and disease control |
These are characteristic findings from clinical research, not diagnostic criteria.
What Should Cardiovascular GH Research Measure?
A comprehensive study should examine more than circulating GH and IGF-1 concentrations.
Depending on the research question, relevant measurements may include echocardiographic cardiac structure, ventricular function, blood pressure, lipid concentrations, glucose regulation and vascular function.
Cardiac magnetic resonance imaging can provide additional information about myocardial structure and tissue characteristics.
Long-term outcomes, including cardiovascular events, are particularly important when evaluating clinical significance.
For example, an improvement in endothelial function does not automatically establish a reduction in cardiovascular disease.
Similarly, changes in left ventricular mass may be beneficial or harmful depending on the underlying condition.
Our growth hormone and ageing article provides further context for age-related changes in endocrine activity.
For UK laboratories exploring growth hormone pathways and peptide-related molecular research, Peptide Lab Direct UK is our featured UK research peptide supplier, offering a specialist platform for research compounds relevant to endocrine signalling and cellular biology.
Frequently Asked Questions
Does growth hormone affect heart function?
Yes. GH and IGF-1 participate in pathways associated with cardiac structure, vascular regulation and myocardial function.
Can growth hormone deficiency affect cardiovascular health?
Yes. Established GH deficiency can be associated with altered cardiac structure, body composition and cardiovascular risk markers.
What happens to the heart in acromegaly?
Chronic GH excess can contribute to cardiac hypertrophy, impaired ventricular relaxation and other cardiovascular abnormalities.
Does IGF-1 influence blood vessels?
Yes. IGF-1 participates in endothelial and vascular smooth muscle signalling, including pathways related to nitric oxide.
Can growth hormone increase blood pressure?
Chronic GH excess is associated with hypertension, partly through fluid retention and changes in vascular regulation.
Is growth hormone proven to prevent heart disease?
No. Evidence of physiological cardiovascular effects does not establish GH as a preventive treatment for cardiovascular disease in healthy adults.
Scientific References
- Isgaard J, Arcopinto M, Karason K, Cittadini A. (2015). GH and the cardiovascular system: an update on a topic at heart. Endocrine.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4328125/ - Neshat N et al. (2026). Cardiovascular Effects of Growth Hormone: From Deficiency to Acromegaly. Cardiology in Review.
https://pubmed.ncbi.nlm.nih.gov/41622549/ - Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management. Endocrine Reviews, 2026.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13577783/ - Lombardi G et al. (2012). The cardiovascular system in growth hormone excess and growth hormone deficiency. Journal of Endocrinological Investigation.
https://pubmed.ncbi.nlm.nih.gov/23143695/
Research-only notice: This article is intended for scientific education and laboratory research. It does not provide medical advice or instructions for administering research compounds.